Document is current
Any future updates will be listed below
-
Authors
Nicolas, Guillaume P. https://orcid.org/0000-0003-0396-5708
Lafont, Manuel Alejandre
McDougall, Lisa
Kaul, Felix
Chirindel, Alin
Weber, Wolfgang
Llmazares, Angela
Johayem, Anass
Baier, Markus
Schubert, Nicole
De Rose, Francesco
Jaafar-Thiel, Leila
Bauman, Andreas
Fani, Melpomeni
Wild, Damian
-
Funding
Funding for this research was provided by:
University of Basel
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 17 April 2025
First Online: 24 May 2025
Declarations
:
: Aproved by the Ethics Committee of Northwest and Central Switzerland (13.03.2024; 2023 − 01981).
: Informed consent was obtained from the patient before the inclusion into the study. The patient gave written informed consent to anonymously use their clinical and imaging data for publication.
: This study is registered with ClinicalTrials.gov (NCT06455358).
: Nuclidium had no influence on the study design and planing of the study. Patent applications on 61Cu-labelled ligands, including [61Cu]Cu-NODAGA-LM3, have been filed by Nuclidium AG, Basel, Switzerland and the University of Basel, Basel, Switzerland, where MF, FDR and LJ are listed as co-inventors. LJ is a co-founder and CEO of Nuclidium AG. FDR, MB and NS is an employees of Nuclidium AG.
